BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pharmexa A/S (PHARMX.CO) To Acquire GemVax AS And Launch Rights Issue To Finance Two Large Phase III Trials In Pancreatic Cancer


10/19/2005 5:13:15 PM

HOERSHOLM, Denmark, April 12 /PRNewswire/ --

  Summary:
  * Pharmexa has entered into an agreement to acquire GemVax AS, a
    private Norwegian biotech company focusing on cancer vaccines
  * The purchase price will be paid in newly issued Pharmexa shares and
    by issuance of a convertible debt instrument
  * To finance the combined product pipeline of the two companies,
    including two large phase III studies in pancreatic cancer,
    Pharmexa intends to launch a rights issue with minimum proceeds of DKK
    150 million and maximum proceeds of approximately DKK 320 million.
  * The acquisition of GemVax and the rights issue are subject to approval
    of Pharmexa's shareholders at the annual general meeting on 29 April
    2005

  Important notice:

This is not the complete press release. To view the complete press release, please see enclosed PDF-file.

http://hugin.info/131680/R/988735/148177.pdf Horsholm, 12 April 2005 Jakob Schmidt Chief Executive Officer Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525

Pharmexa A/S

CONTACT: Jakob Schmidt, Chief Executive Officer of Pharmexa A/S,+45-4516-2525


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->